Skip to main navigation

Work With Us
Contact

Home
About Us
Science
- Publications
Pipeline
UBX1325
Clinical Trials
Investors & Media
Work With Us
Contact
Menu

Investors & Media

Corporate Overview
Press Releases
Events & Presentations
Corporate Governance
SEC Filings
Stock Information
- Stock Quote & Chart
- Analyst Coverage
Investor Resources
- Contact IR
- Investor FAQs

Investor Tools

Print Page
Email Page
Contact IR
Email Alerts
RSS Feeds

Company Overview

UNITY Biotechnology is developing transformative medicines by leveraging fundamental pathways of aging biology, with a focus in retinal diseases.

Stock Information

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Corporate Presentation

Download

Key Data Presentations

Effect of Patient Baseline Characteristics on Response to UBX1325, a Novel Senolytic Candidate For Patients With DME: BEHOLD Phase 2 Study 48 weeks follow-up

ARVO 2024, Presented by Dante Pieramici, M.D.

48-Week End of Study Results from BEHOLD Phase 2 Study of UBX1325 in Patients with DME

EURETINA 2023, Presented by Veeral Sheth, M.D., M.B.A., F.A.C.S., FASRS

View More

Latest Press Releases

UNITY Biotechnology to Participate in Upcoming Investor Conferences

August 12, 2024

UNITY Biotechnology, Inc. Reports Second Quarter 2024 Financial Results and Business Updates

August 6, 2024

View More

In The News

How to kill the ‘zombie’ cells that make you age

May 15, 2024

UNITY Biotech’s CEO on data that builds conviction and pioneering novel treatment paradigms

May 10, 2023

A Drug to Treat Aging May Not Be a Pipe Dream

January 1, 2023

Is longevity more than a billionaire’s pipe-dream?

March 15, 2022

Shooting for longevity and the stars

October 14, 2021

Can Destroying Senescent Cells Treat Age-Related Disease?

March 1, 2020

10 Breakthrough Technologies

February 26, 2020

©2024 Unity Biotechnology. All Rights Reserved.

Terms & Conditions |
Privacy Policy